Titlebook: Geriatric Oncology; Martine Extermann Living reference work 20200th edition Geriatric Oncology.Cancer.Elderly.Biology of Aging and Cancer

Croching

書目名稱Geriatric Oncology影響因子(影響力)




書目名稱Geriatric Oncology影響因子(影響力)學(xué)科排名




書目名稱Geriatric Oncology網(wǎng)絡(luò)公開度




書目名稱Geriatric Oncology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Geriatric Oncology被引頻次




書目名稱Geriatric Oncology被引頻次學(xué)科排名




書目名稱Geriatric Oncology年度引用




書目名稱Geriatric Oncology年度引用學(xué)科排名




書目名稱Geriatric Oncology讀者反饋




書目名稱Geriatric Oncology讀者反饋學(xué)科排名

AND

Aging and Cancer Biology,growth. The available data on the effects of environmental carcinogens on life span and the aging at different levels of integration are critically analyzed. The exposure to various mutagenic agents, i.e., 5-bromodeoxyuridine, alkylating substances, carcinogenic polycyclic aromatic hydrocarbons, nit

眉毛

廢墟

connoisseur

Bladder Cancer in Older Adults, the impact of adjuvant intravesical immunotherapy might be inferior. Patients with muscle-invasive BC (MIBC) may benefit from a multidisciplinary geriatric evaluation. Radical cystectomy (RC) remains the curative treatment to BC, and elderly patients should not be withheld a potentially lifesaving

Ornithologist

Cellular Senescence and Tumor Promotion,cer therapeutic strategies are aimed to induce cancer cells to senesce. However, an excessive accumulation of senescent cells and their secretory phenotype can drive different pathologies associated with age, including cancer. Thus, cellular senescence can begin as a potent tumor suppressive mechani

Ornithologist

Accrue

gene-therapy

Comprehensive Geriatric Assessment (CGA) for Cancer Patients,may be considered initially keeping in mind that they do not replace CGA. If abnormal, screening should be followed by CGA and guided multidisciplinary interventions. This chapter will describe the CGA domains, the most commonly used assessment tools, as well as the benefits of performing such asses

Observe

Diffuse Large B-Cell Lymphomas in Older Adults,ombined modality therapy for limited stage disease, and strategies for the relapsed/refractory older patient. We will also address the issues of prognosis, comorbidities, geriatric assessment, supportive care measures in older patients with DLBCL, and recommendations for assessment and allied care.